Retour

Watch Compare

Xtant Medical Holdings, Inc.

Qualité des données : 100%

XTNT

NYSE Manufacturing Measuring & Analyzing Instruments

0,49 €

▲ 0,01 € (3,15%)

Cap. Boursière: 67,93 M

Prix

0,49 €

Cap. Boursière

67,93 M

Fourchette du Jour

0,45 € — 0,51 €

Fourchette 52 Semaines

0,34 € — 0,95 €

Volume

136 451

Ouverture 0,47 €

Moyenne 50J / 200J

0,59 €

17,55% below

Moyenne 50J / 200J

0,65 €

25,91% below

Quick Summary

Points Clés

Revenue grew 24,77% annually over 5 years — strong growth

ROE of 10,06% — decent returns on equity

Debt/Equity of 0,35 — conservative balance sheet

Generating 10,16 M in free cash flow

P/E of 13,66 — trading at a low valuation

Revenue growth is decelerating — 1Y growth trails 5Y average by 10,56%

Croissance

Revenue Growth (5Y)

24,77%

Au-dessus de la moyenne du secteur (1,82%)

Revenue (1Y)14,21%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

10,06%

Au-dessus de la moyenne du secteur (-53,47%)

ROIC7,20%

Net Margin3,71%

Op. Margin5,44%

Sécurité

Debt / Equity

0,35

Au-dessus de la moyenne du secteur (0,31)

Current Ratio2,21

Interest Coverage1,98

Valorisation

PE (TTM)

13,66

Au-dessus de la moyenne du secteur (-1,47)

P/B Ratio1,35

EV/EBITDA5,99

Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)

Métrique	Action	Médiane du Secteur
P/E	13,7	-1,5
P/B	1,4	1,6
ROE %	10,1	-53,5
Net Margin %	3,7	-41,5
Rev Growth 5Y %	24,8	1,8
D/E	0,4	0,3

ETFs Holding This Stock

BRSIX BRSIX

0,09% weight

All Fundamental Metrics

Growth
Revenue Growth (1Y)	14,21%	Revenue Growth (3Y)	21,11%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	174,50%
Revenue Growth (5Y)	24,77%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	133,93 M	Net Income (TTM)	4,97 M
ROE	10,06%	ROA	4,74%
Gross Margin	62,92%	Operating Margin	5,44%
Net Margin	3,71%	Free Cash Flow (TTM)	10,16 M
ROIC	7,20%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,35	Current Ratio	2,21
Interest Coverage	1,98	Asset Turnover	1,28
Working Capital	42,83 M	Tangible Book Value	36,02 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	13,66	Forward P/E	N/A
P/B Ratio	1,35	P/S Ratio	0,51
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	5,99	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	14,96%
Market Cap	67,93 M	Enterprise Value	74,94 M
Per Share
EPS (Diluted TTM)	0,03	Revenue / Share	0,96
FCF / Share	0,07	OCF / Share	0,09
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	1,78%	FCF Conversion	204,38%
SBC-Adj. FCF	6,86 M	Growth Momentum	-10,56

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	133,93 M	117,27 M	91,30 M	57,97 M	55,26 M
Net Income	4,97 M	-16,45 M	660 000,0	-8,49 M	-4,85 M
EPS (Diluted)	0,03	-0,12	0,01	-0,09	-0,06
Gross Profit	84,27 M	68,22 M	55,47 M	32,14 M	32,49 M
Operating Income	7,28 M	-12,07 M	-10,16 M	-6,76 M	-3,85 M
EBITDA	—	—	—	—	—
R&D Expenses	2,10 M	2,39 M	1,34 M	915 000,0	870 000,0
SG&A Expenses	—	—	—	—	—
D&A	5,22 M	4,22 M	3,17 M	1,29 M	1,33 M
Interest Expense	3,67 M	4,16 M	2,94 M	1,69 M	995 000,0
Income Tax	2,03 M	187 000,0	-1,70 M	69 000,0	296 000,0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	94,15 M	93,84 M	92,61 M	60,23 M	54,69 M
Total Liabilities	43,19 M	50,87 M	41,26 M	26,06 M	23,81 M
Shareholders' Equity	50,95 M	42,96 M	51,35 M	34,17 M	30,88 M
Total Debt	11,03 M	22,04 M	17,17 M	9,69 M	11,79 M
Cash & Equivalents	17,05 M	6,20 M	5,72 M	20,30 M	18,24 M
Current Assets	78,25 M	67,12 M	64,87 M	49,32 M	44,33 M
Current Liabilities	29,48 M	28,58 M	22,99 M	15,22 M	11,08 M